IL-17 and IL-22 in immunity: Driving protection and pathology

European Journal of Immunology

Volumn 47, Issue 4, 2017, Pages 607-614

  Eyerich, Kilian ^a   Dimartino, Valentina ^b   Cavani, Andrea ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INMP   (Italy)

Author keywords

autoimmune diseases; cytokines; Th17; Th22

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ALLERGIC DISEASE; ARTICLE; AUTOIMMUNE DISEASE; CANCER GROWTH; CARCINOGENESIS; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; INFECTION; INTESTINE; LUNG; NEOPLASM; REGENERATION; SKIN; TH17 CELL;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNITY; INFECTION; INTERLEUKIN-17; INTERLEUKINS; INTESTINES; LUNG; NEOPLASMS; REGENERATION; SIGNAL TRANSDUCTION; SKIN; TH17 CELLS;

EID: 85017257071     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646723     Document Type: Article

References (95)

1. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009. 27: 485–517.
2. Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A. and Sallusto, F., Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009. 10: 857–863.
3. Trifari, S. and Spits, H., IL-22-producing CD4+ T cells: middle-men between the immune system and its environment. Eur. J. Immunol. 2010. 40:2369–2371.
4. Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F. et al., Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 2009. 119: 3573–3585.
5. Beringer, A., Noack, M. and Miossec, P., IL-17 in chronic inflammation: from discovery to targeting. Trends. Mol. Med. 2016. 22: 230–241.
6. Iwakura, Y., Ishigame, H., Saijo, S. and Nakae, S., Functional specialization of interleukin-17 family members. Immunity 2011. 34: 149–162.
7. Basu, R., Hatton, R. D. and Weaver, C. T., The Th17 family: flexibility follows function. Immunol. Rev. 2013. 252: 89–103.
8. Montaldo, E., Juelke, K. and Romagnani, C., Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur. J. Immunol. 2015. 45: 2171–2182.
9. Taylor, P. R., Roy, S., Leal, S. M., Sun, Y., Howell, S. J., Cobb, B. A., Li, X. et al., Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 2014. 15: 143–151.
10. Keijsers, R. M. C., Hendriks, A. G. M., van Erp, P. E. J., van Cranenbroek, B., van de Kerkhof, P. C. M., Koenen, H. J. P. M. et al., In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17. J. Invest. Dermatol. 2014. 134: 1276–1284.
11. Gao, W., Wu, Y., Tian, Y. and Ni, B., Yin-Yang regulation of RORγt protein complex in Th17 differentiation. Int. Rev. Immunol. 2015. 34: 295–304.
12. Maggi, L., Santarlasci, V., Capone, M., Peired, A., Frosali, F., Crome, S. Q., Querci, V. et al., CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 2010. 40: 2174–2181.
13. Diller, M. L., Kudchadkar, R. R., Delman, K. A., Lawson, D. H. and Ford, M. L., Balancing inflammation: the link between Th17 and regulatory T cells. Mediators Inflamm. 2016. 2016: 6309219. doi: 10.1155/2016/6309219. Epub 2016 Jun 19.
14. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006. 441: 235–238.
15. Santarlasci, V., Maggi, L., Capone, M., Frosali, F., Querci, V., De Palma, R., Liotta, F. et al., TGF-β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur. J. Immunol. 2009. 39: 207–215.
16. Acosta-Rodriguez E, V., Napolitani, G., Lanzavecchia, A. and Sallusto, F., Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007. 8: 942–949.
17. Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S. et al., Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β;. Nature 2012. 484: 514–518.
18. Noster, R., de Koning, H. D., Maier, E., Prelog, M., Lainka, E. and Zielinski, C. E., Dysregulation of proinflammatory versus anti-inflammatory human TH17 cell functionalities in the autoinflammatory Schnitzler syndrome. J. Allergy Clin. Immunol. 2016. 138: 1161–1169.
19. Zielinski, C. E., Autoimmunity beyond Th17: GM-CSF producing T cells. Cell Cycle 2014. 13: 2489–2490.
20. Zhou, L., Ivanov, I., Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E. et al., IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007. 8: 967–974.
21. Rutz, S., Eidenschenk, C. and Ouyang, W., IL-22, not simply a Th17 cytokine. Immunol. Rev. 2013. 252: 116–132.
22. Rutz, S., Noubade, R., Eidenschenk, C., Ota, N., Zeng, W., Zheng, Y., Hackney, J. et al., Transcription factor c-Maf mediates the TGF-β-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol. 2011. 12: 1238–1245
23. Moreira-Teixeira, L., Resende, M., Coffre, M., Devergne, O., Herbeuval, J. P., Hermine, O., Schneider, E. et al., Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells. J. Immunol. 2011. 186: 5758–5765
24. Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L. et al., Generation of pathogenic T(h)17 cells in the absence of TGF-b signalling. Nature 2010. 467: 967–971.
25. Gurney, A. L., IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int. Immunopharmacol. 2004. 4: 669–677.
26. Ramirez, J. M., Brembilla, N. C., Sorg, O., Chicheportiche, R., Matthes, T., Dayer, J. M., Saurat, J. H. et al., Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur. J. Immunol. 2010. 40: 2450–2459.
27. Kotenko, S. V., Izotova, L. S., Mirochnitchenko, O. V., Esterova, E., Dickensheets, H., Donnelly, R. P. and Pestka, S., Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J. Immunol. 2001. 166: 7096–7103
28. Eyerich, K., Foerster, S., Rombold, S., Seidl, H.-P., Behrendt, H., Hofmann, H., Ring, J. et al., Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J. Invest. Dermatol. 2008. 128: 2640–2645.
29. Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M. et al., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011. 332: 65–68.
30. Isailovic, N., Daigo, K., Mantovani, A. and Selmi, C., Interleukin-17 and innate immunity in infections and chronic inflammation. J. Autoimmun. 2015. 60: 1–11.
31. O'Connor, W., Jr., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, I. Y., Kolls, J. K. et al., A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 2009; 10:603–609.
32. Pennino, D., Eyerich, K., Scarponi, C., Carbone, T., Eyerich, S., Nasorri, F., Garcovich, S. et al., IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J. Immunol. 2010. 184: 4880–4888.
33. Chiricozzi, A., Nograles, K. E., Johnson-Huang, L. M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K. M., Gulati, N. et al., IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014. 9: e90284.
34. Albanesi, C., Cavani, A. and Girolomoni, G., IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J. Immunol. 1999. 162: 494–502.
35. Moran, E. M., Mullan, R., McCormick, J., Connolly, M., Sullivan, O., Fitzgerald, O., Bresnihan, B. et al., Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis. Res. Ther. 2009. 11: R113
36. Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yi Yu, G., Vallabhapurapu, S., Scheller, J. et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009. 15: 103–113.
37. Kinugasa, T., Sakaguchi, T., Gu, X. and Reinecker, H. C., Claudins regulate the intestinal barrier in response to immune mediators, Gastroenterology. 2000. 118: 1001–1011
38. Sonnenberg, G. F., Fouser, L. A. and Artis, D., Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 2011. 12: 383–390
39. Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R. et al., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 2008. 14: 282–289.
40. Wolk, K., Witte, E., Wallace, E., Döcke, W. D., Kunz, S., Asadullah, K., Volk, H. D. et al., IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 2006. 36: 1309–1323
41. Aujla, S. J. and Kolls, J. K., IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 2009. 87: 451–454.
42. Zhao, M., Li, Y. and Xiao, W., Anti-apoptotic effect of interleukin-22 on fibroblast-like synoviocytes in patients with rheumatoid arthritis is mediated via the signal transducer and activator of transcription 3 signaling pathway. Int. J. Rheum. Dis. 2016. Aug 4. doi: 10.1111/1756-185X.12939. [Epub ahead of print]
43. Cobleigh, M. A. and Robek, M. D., Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis. Am. J. Pathol. 2013. 182: 21–28.
44. Huan, C., Kim, D., Ou, P., Alfonso, A. and Stanek, A., Mechanisms of interleukin-22's beneficial effects in acute pancreatitis. World J. Gastrointest. Pathophysiol. 2016. 7: 108–116.
45. Avitabile, S., Odorisio, T., Madonna, S., Eyerich, S., Guerra, L., Eyerich, K., Zambruno, G. et al., Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing functions. J. Invest. Dermatol. 2015. 135: 2862–2870
46. Boehncke, W.-H. and Schön, M. P., Psoriasis. Lancet. 2015. 386: 983–994.
47. Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y. and Blauvelt, A., Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 2010. 130: 1373–1383.
48. Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G. et al., The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 2014. 5: 5621. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25470744.
49. Arakawa, A., Siewert, K., Stohr, J., Besgen, P., Kim, S. M., Ruhl, G., Nickel, J. et al., Melanocyte antigen triggers autoimmunity in human psoriasis. J. Exp. Med. 2015. 212: 2203–2212.
50. Cheung, K. L., Jarrett, R., Subramaniam, S., Salimi, M., Gutowska-Owsiak, D., Chen, Y.-L., Hardman, C. et al., Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J. Exp. Med. 2016. 213: 2399–2412.
51. Rizzo, H. L., Kagami, S., Phillips, K. G., Kurtz, S. E., Jacques, S. L. and Blauvelt, A., IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011. 186: 1495–1502.
52. Cochez, P. M., Michiels, C., Hendrickx, E., Van Belle, A. B., Lemaire, M. M., Dauguet, N., Warnier, G. et al., AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model. Eur. J. Immunol. 2016. 46: 1449–1459
53. Wolk, K., Haugen, H. S., Xu, W., Witte, E., Waggie, K., Anderson, M., Vom Baur, E. et al., IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. (Berl). 2009. 87: 523–536
54. Nikamo, P., Cheuk, S., Lysell, J., Enerba, C., Bergh, K., Lande, N. X., Eidsmo, L. et al., Genetic Variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells. J. Inest. Dermatol. 2014. 134: 1535–1541
55. Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 2015. 11: 415–429.
56. Kim, K. W., Kim, H. R., Kim, B. M., Cho, M. L. and Lee, S. H., Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am. J. Pathol. 2015. 185: 3011–3024
57. Metawi, S. A., Abbas, D., Kamal, M. M. and Ibrahim, M. K., Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin. Rheumatol. 2011. 30: 1201–1207
58. Kirkham, B. W., Lassere, M. N., Edmonds, J. P., Juhasz, K. M., Bird, P. A., Lee, C. S. et al., Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE Study cohort). Arthritis. Rheum. 2006. 54: 1122–1131
59. Nakae, S., Nambu, A., Sudo, K. and Iwakura, Y., Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003. 171: 6173–6177
60. Benedetti, G. and Miossec, P., Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur. J. Immunol. 2014. 44: 339–347.
61. Hot, A. and Miossec, P., Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann. Rheum. Dis. 2011. 70: 727–732
62. Lee, S.-Y., Kwok, S.-K., Son, H.-J., Ryu, J.-G., Kim, E.-K., Oh, H.-J., Cho, M.-L. et al., IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res. Ther. 2013. 15: R31.
63. Toh, M. L., Gonzales, G., Koenders, M. I., Tournadre, A., Boyle, D., Lubberts, E., Zhou, Y. et al., Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One. 2010. 5: 1–13.
64. Kunwar, S., Dahal, K. and Sharma, S., Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol. Int. 2016. 36: 1065–1075.
65. Zhang, L., Li, Y., Li, Y., Qi, L., Liu, X., Yuan, C., Hu, N. et al., Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. Plos One. 2012. 7: e31000
66. Kim, K. W., Kim, H. R., Park, J. Y., Park, J. S., Oh, H. J., Woo, Y. J., Park, M. K. et al., Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthr. Rheumatol. 2012. 64: 1015–1023.
67. Geboes, L., Dumoutier, L., Kelchtermans, H., Schurgers, E., Mitera, T., Renauld, J. C. and Matthys, P., Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthr. Rheum. 2009. 60: 390–395.
68. Corneth, O. B. J., Reijmers, R. M., Mus, A. M. C., Asmawidjaja, P. S., van Hamburg, J. P., Papazian, N., Siegers, J. Y. et al., Loss of IL-22 inhibits autoantibody formation in collagen-induced arthritis in mice. Eur. J. Immunol. 2016. 46: 1404–1414.
69. Sarra, M., Pallone, F., Macdonald, T. T. and Monteleone, G., IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010. 16: 1808–1813
70. Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P. et al., Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661–678
71. O'Connor, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K. et al., A protective function for interleukin 17A in T cell–mediated intestinal inflammation. Nat. Immunol. 2009. 10: 603–609.
72. Maxwell, J. R., Zhang, Y., Brown, W. A., Smith, C. L., Byrne, F. R., Fiorino, M., Stevens, E. et al., Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity 2015. 43: 739–750
73. Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J. et al., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012. 61: 1693–1700
74. Kamada, N., Seo, S. U., Chen, G. Y. and Núñez, G., Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013. 13: 321–335
75. Lindemans, C. A., Calafiore, M., Mertelsmann, A. M., Margaret, H., Connor, O., Dudakov, J. A., Jenq, R. R. et al., Interleukin-22 promotes intestinal stem cell-mediated epithelial regeneration. Nature 2016. 528: 560–564.
76. Zenewicz, L. A., Yancopoulos, G. D., Valenzuela, D. M., Murphy, A. J., Stevens, S. and Flavell, R. A., Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008. 29: 947–957.
77. Sugimoto, K., Ogawa, A., Mizoguchi, E., Shimomura, Y., Andoh, A., Bhan, A. K., Blumberg, R. S. et al., IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 2008. 118: 534–544
78. Eyerich, K., Pennino, D., Scarponi, C., Foerster, S., Nasorri, F., Behrendt, H., Ring, J. et al., IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J. Allergy Clin. Immunol. 2009. 123:59–66.
79. Massoud, A. H., Charbonnier, L., Lopez, D., Pellegrini, M., Phipatanakul, W. and Chatila, T. A., An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to T H 17-like cells. Nat. Med. 2016. 22: 1–13.
80. Cosmi, L., Liotta, F. and Annunziato, F., Th17 regulating lower airway disease. Curr. Opin. Allergy Clin. Immunol. 2016. 16: 1–6.
81. Nakagome, K., Imamura, M., Kawahata, K., Harada, H., Okunishi, K., Matsumoto, T., Sasaki, O. et al., High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10–associated mechanism. J. Immunol. 2011. 187: 5077–5089.
82. Pennino, D., Bhavsar, P. K., Effner, R., Avitabile, S., Venn, P., Quaranta, M., Marzaioli, V. et al., IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J. Allergy Clin. Immunol. 2013. 131: 562–570.
83. Johnson, J. R., Nishioka, M., Chakir, J., Risse, P.-A., Almaghlouth, I., Bazarbashi, A. N., Plante, S. et al., IL-22 contributes to TGF-β1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. Respir. Res. 2013. 14: 118.
84. Czarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., Khattri, S. et al., Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J. Allergy Clin. Immunol. 2015. 136: 104–115.
85. Nardinocchi, L., Sonego, G., Passarelli, F., Avitabile, S., Scarponi, C., Failla, C. M., Simoni, S. et al., Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur. J. Immunol. 2015. 45: 922–931.
86. Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D. and Yu, H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009. 206: 1457–1464.
87. Wilke, C. M., Kryczek, I., Wei, S., Zhao, E., Wu, K., Wang, G. and Zou, W., Th17 cells in cancer: Help or hindrance? Carcinogenesis. 2011. 32:643–649.
88. Yang, B., Kang, H., Fung, A., Zhao, H., Wang, T., Ma, D., Numasaki, M. et al., The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014. 2014: 623759.
89. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008. 112: 362–373.
90. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P. et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009. 31: 787–798.
91. Lim, C. and Savan, R., The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 2014. 25: 257–271.
92. Wen, Z., Liao, Q., Zhao, J., Hu, Y., You, L., Lu, Z., Jia, C. et al., High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 2014. 21: 125–132
93. Zhuang, Y., Peng, L. S., Zhao, Y. L., Shi, Y., Mao, X. H., Guo, G., Chen, W. et al., Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol. Immunother. 2012. 61: 1965–1975
94. Wu, T., Cui, L., Liang, Z., Liu, C., Liu, Y. and Li, J., Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clin. Immunol. 2013. 147: 38–39.
95. Yu, H., Pardoll, D. and Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009. 9: 798–809